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(e.g. Fig. 2). As found with the earlier sulphonylureas,
therefore, the major effect of chlorpropamide is in the basal
or fasting blood-sugar level, rather than on the disposal of
ingested carbohydrates.
CWorpropamide was found in this series to be frequently
very effective where there was primary or secondary tolbuta-
mide failure (e.g. fO . 19 in Fig. 1). In some instances 1
tablet of chlorpropamide (250 mg.) was more effective than
6 tablets of tolbutamide (3 g.). It would appear unlikely then
that there is a purely quantitative difference in action of these
drugs, but we performed no studies of blood levels.
This series is plainly not large enough to judge the
toxicity of the drug, which has been implicated in the appear-
ance of jaundice in certain cases overseas. Its more powerful
hypoglycaemic effect may .give rise to serious reactions,
though we have seen none.
It would appear that chlorpropamide may be effective in
maturity-onset diabetes, whatever the age, sex or body
build of the patient, whatever the duration of diabetes, what-
ever response there had been to tolbutamide, and whether
or not insulin had been used previously.
Our present practice is to start with tolbutamide (maximum
dose 1 g. 3 times a day) where a sulphonylurea appears
indicated (i.e. in maturity-onset cases in which diet alone has
failed). If the response is not satisfactory, or if secondary
failure Qccurs, a trial of cWorpropamide is made.
SUMMARY
1. The response to chlorpropamide has been assessed in 56
diabetic patients, all but 4 being of maturity-onset type.
2. The drug was satisfactory in a high proportion of cases,
and appears to be particularly useful in patients in whom
there has been primary or secondary tolbutamide failure.
3. 0 serious toxic effects were seen in this series:
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Metahexamide* is a sulphonyl urea derivative, N. 3 amino 4
methylbenzol-sulphonyl- Tl-cyclohexylureum, with a structur-
al formula (compared with tolbutamide) as follows:





Like its analo~ues, tolbutamide and chlorpropamide, it is
capable of lowerIng the blood sugar in normal subjects and
in some diabetics; not in diabetes of the juvenile type. Its
breakdown and excretion are slower than with tolbutamide
the blood level being reduced 50% from a maximum in abou~
20 hours.
Toxic Effects in Man
Occasional allergic skin reactions and gastro-intestinal
irritation appeared to be the only effects of metahexamide at
first. Unfortunately, while we were in the process of perform-
ing a clinical trial of this substance, the makers reported that
sev~re he~ati~ disturbances had occurred in some patients
while taking Jt, and consequently they very correctly with-
drew all supplies.
We" report below, briefly and for record purposes our
results until the cessation of the trial. '
• T~e metahexamide and the scientific data thereon were kiJIdly
supJ?hed by Messr~. Hoec.hst Pharmaceuticals of South Africa.
Nonstan Laboratones (Pretoria) also supplied some tablets which
had not been used by the time the trial was discontinued. '
Methods
The patients chosen for the trial had diabetes of maturity-
onset type, had never had ketosis and, except one, were all
over 40. The duration of their diabetes varied from 1 to 20
years, and just over half had received insulin previously. All
cases, however, had failed to respond adequately to both diet
and tolbutamide, so that this trial aimed at being rather a
searching test for metahexamide. .
The subjects were out-patients attending a diabetic clinic
and seen for the most part weekly. Several fasting blood
sugars were estimated iri the weeks before metahexamide
was started, while the patient was taking no drug or was
on tolbutamide only. Urine samples were tested at the
clinic and also by the patient at home. In some cases the
24-hour urine sugar was estimated on several occasions.
Weekly weight records were kept. As discussed previously,l
we consider it essential that a period on no treatment other
than diet should precede the evaluation of an oral drug.
The patients were started on 50 or 100 mg. of metahexamide
and this was increased gradually to a maximunl of 300 mg.,
taken in a single daily dose.
Results
Results are classed as 'success' if the blood sugar is brought
within normal range (though we realize that carbohydrate
tolerance may still be grossly abnormal) and the urine tests
showed 'nil' or 'trace'. A 'partial success' indicates a distinct
imprQvement, and 'failure' no apparent effect at all.
The patients receiving the drug numbered 28, and the
effects are assessed in 27; one patient had to stop therapy
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27
because of nausea, vomiting and headaches. The make-up
of the patients was as follows:
PRlOR RESPONSE TO TOLBUTAMIDE
Primary failure .. 13
Secondary failure, following initial success 1I
Partial success 3
27




The 3 'successes' were aged 32,65 and 71; none was obese;
the 2 older patients had never had insulin. The response of
the younger patIent is shown in Fig. I.
The response to metahexamide bore no relation to the
tolbutamide response; for instance, I 'success' and 3 'partial
successes' had been primary tolbutamide failures.
No obvious trend in total white-cell count or serum-
cholesterol level was evident from metahexamide therapy.
The serum cholesterol in one patient, however, who responded
successfully to metahexamide, dropped from 237 mg. per
100 ml. to 179 in 10 weeks (Fig. 1). These were the only
. levels obtained in that patient.
Commellt
Body build. It is noteworthy that on analysis of our figures
we found not a single over-weight patient in the White racial
group who received metahexamide, although the patients in
the trial were quite unselected, apart from being tolbutamide
failures and able to attend regularly. This indicates our
reluctance to use the sulphonyl-ureas in obese subjects, who
are better treated by dietary measures. In the poorer,
Coloured patients the position is different-it is usually
impossible to achieve success with diets in these people.
Efficacy of metahexamide. The results of metahexamide in
tolbutamide-failed cases were not impressive-nevertheless a
maximum of only 300 mg. of metahexamide was used, as
againste 1 - 3 g. per day of tolbutamide. Where it does work,
metahexamide would appear to be more powerful, dose for
dose.
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Fig. 1. This shows one of the more satisfactory responses to
metahexamide. The patient was the only one in the series under
40 years of age, and had failed previously to respond adequately
to tolbutamide. The high blood-sugar level with a corresponding
peak in urine sugar foUowing a period of 5 days without therapy
is noteworthy.
SUMMARY
A trial of metahexamide was made in a group of diabetic
patients who were believed to be suitable for oral sulphonyl-
urea therapy but who had failed to respond adequately to
tolbutamide. A few responded better to metahexamide but
on the whole the results were disappointing. Metahexamide is
no longer available.
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MEDICAL SERVICES PLAN : PROGRESS REPORT
The Medical Services Plan accepted applications for group mem-
bership from the general public as from I July 1959 and tbereby
launched th.e first comprehensive, profession-sponsored, pre-paid
medical care scheme on the African continent. After 6 months
of operation, this report is being circulated because of numerous
requests about the progress of the Plan. ]t is hoped that the data
contained herein will bring each participating doctor up to date
on the present and anticipated future developments of the Plan.
A. Fiscal
]n order to give the Plan the initial funds necessary for estab-
lishing the scheme, it was decided to ask each participating doctor
for a participation loan of £10. This loan is repayable upon the
resignation or death of the doctor, or when the financial stability
of the Plan warrants it. Originally, participating doctor member-
ship was limited to the area of the Southern Tran vaal Branch
of tbe Medical Association of South Africa, but was extended
to cover the doctors in the area of the East Rand Branch at the
request of that Branch. From these areas 764 doctors indicated
their intention of joining the Medical Services Plan as participating
doctors, of whom 691 have submitted their participation loan.
There are 73 still outstanding.
An amount of £1,956 125. 7d. has been used up to September
1959 to cover costs of establishing the Plan. Included in this
amount is capital expenditure for printing (stationery, envelopes,
doctors' and subscribers' agreements, intention card, applica-
